Drugs / AFA-281
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05547503 | Apr 2023 → Dec 2024 | inflammatory disease, neuropathy, painful | Afasci Inc | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06719908 Comparator | Jul 2025 → Jul 2026 overdue | alcohol-related disorders | Afasci Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06649747 Comparator | Apr 2027 → Mar 2032 expected | radiculopathy | Afasci Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06710431 Comparator | Oct 2025 → Jun 2027 expected | alcohol abuse, alcohol dependence, anxiety, depressive disorder +1 | Afasci Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFA-281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06649747 ↗ |
| Modality | Small molecule | “A small molecule, orally available” NCT06649747 ↗ |
| Route | Oral | “Oral capsules will be administered in dose titration and split daily dose in fours time daily (QID) for 14 - 21 consecutive days.” NCT05547503 ↗ |